Effects of a combination of 2 MG estradiol valerate and 3 MG dienogest on coagulation, lipid profile, and glucose metabolism in postmenopausal women

Drugs of Today

Volumn 37, Issue SUPPL. G, 2001, Pages 87-99

  Graser T ^a   Muller A ^a   Druckman, R ^a   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; ESTRADIOL VALERATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTICLE; BLOOD CLOTTING; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FEMALE; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VAGINA ATROPHY; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0034792765     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. European and North American experience with HRT for the prevention of osteoporosis
2. Cardio-vascular benefits of estrogen replacement therapy
3. Estrogens, lipids and cardiovascular disease: No easy answer
4. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestogen therapy in postmenopausal women
5. A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women
6. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy
7. Guidance for clinical evaluation of combined estrogen/progestin-containing drug products used for hormone replacement therapy of postmenopausal women
8. Diabetes and heart disease in women
9. The sex differential in morbidity, mortality, and lifestyle
10. Estrogen replacement therapy and the risk of venous thrombosis
11. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors
12. Risk of venous thromboembolism in users of hormone replacement therapy
13. Hormone replacement therapy with estradiol and risk of venous thromboembolism: A population-based study in Southern Europe
14. Organ targeting with the oral progestin dienogest
15. A 19-norprogestin without a 17-ethinyl group. II: Dienogest from a pharmacodynamic point of view
16. Introduction: Structure-function relationships, metabolism, pharmacokinetics and potency of progestins
17. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - A dose-ranging study
18. Coagulation activation following estrogen administration to postmenopausal women
19. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices
20. Exercise, nutrition, and the coagulation effects of estrogen replacement on cardiovascular health
21. Estrogen and the risk of coagulopathy
22. Effects of progestogens on haemostasis
23. The effects of transdermal estradiol and oral conjugated estrogens on hemostasis variables
24. Sexual steroids and haemostasis
25. Estrogen and coronary heart disease in women
26. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
27. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
28. Lipoprotein and apolipoprotein levels in postmenopausal women on continuous estrogen/progestogen therapy
29. Hormone replacement therapy: Lipid responses to continuous combined estrogen and progestogen versus estrogen monotherapy
30. Apoproteins B and A1 and coronary artery disease in humans
31. Five years with continuous combined estrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern
32. Sex differences in insulin levels in older adults and the effect of body size, estrogen replacement therapy, and glucose tolerance status
33. A comparison of the effects of oral and transdermal estrogen replacement therapy on insulin sensitivity in postmenopausal women
34. Combined continuous hormone replacement therapy: A critical review